Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Long-Term Study to Assess the Safety and Efficacy of AXS-07 (MoSEIC™ Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults

NCT04068051 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.

NCT NCT04068051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Long-Term Study to Assess the Safety and Efficacy of AXS-07 (MoSEIC™ Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults
Lead sponsor
Axsome Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 6, 2019
Completion date
September 22, 2020
Enrollment
706 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

migraine